Novo Nordisk Sues Hims & Hers Over Weight-Loss Drug Knockoffs
Danish pharma giant Novo Nordisk files patent lawsuit against telehealth company Hims & Hers for selling unauthorized versions of Wegovy and Ozempic weight-loss medications.
/ 33 items
#HIMS↓
Hims Pulls Copycat Wegovy Weight-Loss Pill After Federal Pressure
Hims & Hers Health stops selling its cheaper Wegovy copycat pill just two days after launch following FDA crackdown and Justice Department investigation into compounded weight-loss drugs.
FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.
Hims vs. Novo Nordisk: Why the Pharma Giant Might Avoid a Legal Fight
Hims is selling a $49 copycat of Novo Nordisk's $149 weight-loss pill, but legal experts say Novo may avoid court battles due to risks of setting dangerous precedents.
FDA Commissioner Warns Against "Illegal Copycat" Weight-Loss Drugs
FDA takes aim at compounded weight-loss drugs like Hims' $49 Wegovy alternative, raising safety concerns over unapproved copycat medications flooding the market.
Hims & Hers Launches $49 Wegovy Alternative, Shaking Up Weight Loss Market
Hims & Hers offers compounded semaglutide pill at $49/month introductory price, significantly undercutting Novo Nordisk's $199 Wegovy brand-name treatment with same active ingredient.